Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosingROSENSTOCK, Julio; REUSCH, Jane; BUSH, Mark et al.Diabetes care. 2009, Vol 32, Num 10, pp 1880-1886, issn 0149-5992, 7 p.Article

HARMONY 3:104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking MetforminAHREN, Bo; JOHNSON, Susan L; STEWART, Murray et al.Diabetes care. 2014, Vol 37, Num 8, pp 2141-2148, issn 0149-5992, 8 p.Article

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin LisproROSENSTOCK, Julio; FONSECA, Vivian A; LEITER, Lawrence A et al.Diabetes care. 2014, Vol 37, Num 8, pp 2317-2325, issn 0149-5992, 9 p.Article